SteraMist to be Used in a Global Influenza Vaccine Facility in Australia
Company Continues To See Strong Bookings and A Robust Pipeline For Its Custom Engineered Systems in The Life Science Sector
FREDERICK, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announced that SteraMist is to be utilized by a world-renowned influenza vaccine company that focuses on innovative research, transformative technologies, production, and distribution.
TOMI’s Australian partner, Critical Scientific Solutions, was recently awarded the $280,000 purchase order in the third quarter of this year for three modified SteraMist Environment Systems and TOMI’s stainless steel 90-degree applicators to be used in this prestigious influenza vaccine company’s labs to decontaminate their cleanrooms and penetrate HEPA filters to decontaminate ductwork.
“With the 24/7 assistance of TOMI’s COO and Tech Team, we were able to win this tender against multiple competitors,” Keith Wilson, Sales Manager of Critical Scientific Solutions, stated. “We became TOMI’s partner at the end of last year and have gained traction in Australia and New Zealand with many additional open opportunities to close.”
Elissa J. (E.J.) Shane, COO of TOMI, stated, “Since their initial purchase late last year, Critical Scientific Solutions has been a steadfast partner and service provider, able to enter the Australian and New Zealand markets quickly with an understanding of the advantages of SteraMist technology and a targeted focus in the Life Sciences. We are looking forward to pursuing future opportunities through this valuable partnership. We continue to see strong demand for our custom engineered systems in the Life Science sector which provides an expanding base of stable and recurring BIT solution demand over the life of the systems.”
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to anticipated financial performance and operating results, including result for the March quarter in 2022; expected growth in sales and market demand; intent to sell shares by the management; revenue opportunities of CES products and timing of revenue recognition; growth strategies of the company; anticipated manufacturing capability; and trading price of common stock. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Jennifer Belodeau
IMS Investor Relations
tomi@imsinvestorrelations.com
